Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 2 (February)

1. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
   Lancet Oncol, 8(2): 119-27. [Abstract] [Full-text]
2. Small cell carcinoma of the breast.
   Semin Oncol, 34(1): 64-6. [Abstract] [Full-text]
3. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis.
   Cancer Sci, 98(3): 315-20. [Abstract] [Full-text]
4. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.
   Cancer Immunol Immunother, 56(4): 527-33. [Abstract] [Full-text]
5. Sentinel lymph node biopsy is feasible even after total mastectomy.
   J Surg Oncol, 95(2): 175-9. [Abstract] [Full-text]
6. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
   Int J Cancer, 120(7): 1451-8. [Abstract] [Full-text]
7. Breast conservation: current results and future perspectives at the European Institute of Oncology.
   Int J Cancer, 120(7): 1381-6. [Abstract] [Full-text]
8. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.
   Int J Cancer, 120(7): 1536-41. [Abstract] [Full-text]
9. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer.
   Int J Cancer, 120(7): 1523-8. [Abstract] [Full-text]
10. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
    Int J Cancer, 120(7): 1434-43. [Abstract] [Full-text]
11. Management of early breast cancer in the elderly.
    Int J Cancer, 120(6): 1155-60. [Abstract] [Full-text]
12. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.
    Int J Cancer, 120(6): 1261-7. [Abstract] [Full-text]
13. Risk for breast cancer among women with endometriosis.
    Int J Cancer, 120(6): 1372-5. [Abstract] [Full-text]
14. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer.
    Int J Cancer, 120(6): 1311-7. [Abstract] [Full-text]
15. High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis.
    Int J Cancer, 120(6): 1169-78. [Abstract] [Full-text]
16. Recent trends in breast cancer incidence among 6 Asian groups in the Greater Bay Area of Northern California.
    Int J Cancer, 120(6): 1324-9. [Abstract] [Full-text]
17. Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines.
    Int J Cancer, 120(6): 1179-91. [Abstract] [Full-text]
18. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Cancer Res, 67(3): 1352-60. [Abstract] [Full-text]
19. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase.
    Cancer Res, 67(3): 1282-90. [Abstract] [Full-text]
20. TSP50 encodes a testis-specific protease and is negatively regulated by p53.
    Cancer Res, 67(3): 1239-45. [Abstract] [Full-text]
21. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.
    Cancer Res, 67(3): 1203-11. [Abstract] [Full-text]
22. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Cancer Res, 67(3): 1170-5. [Abstract] [Full-text]
23. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice.
    Cancer Res, 67(3): 1138-44. [Abstract] [Full-text]
24. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk.
    Cancer Res, 67(3): 868-70. [Abstract] [Full-text]
25. Breast cancer: should gastrointestinal bacteria be on our radar screen?
    Cancer Res, 67(3): 847-50. [Abstract] [Full-text]
26. Marginal modeling of nonnested multilevel data using standard software.
    Am J Epidemiol, 165(4): 453-63. [Abstract] [Full-text]
27. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    J Natl Cancer Inst, 99(3): 196-205. [Abstract] [Full-text]
28. Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.
    BMC Cancer, 7: 26. [Abstract] [Full-text]
29. NHSBSP type 1 interval cancers: a scientifically valid grouping?
    Clin Radiol, 62(3): 262-7. [Abstract] [Full-text]
30. Role of ultrasonography and MRI in the detection of wide intraductal component of invasive breast cancer--a prospective study.
    Clin Radiol, 62(3): 252-61. [Abstract] [Full-text]
31. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer.
    Cancer, 109(4): 650-7. [Abstract] [Full-text]
32. Heregulinbeta activates store-operated Ca2+ channels through c-erbB2 receptor level-dependent pathway in human breast cancer cells.
    Arch Biochem Biophys, 458(2): 244-52. [Abstract] [Full-text]
33. MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines.
    J Biol Chem, 282(7): 4243-52. [Abstract] [Full-text]
34. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Int J Radiat Oncol Biol Phys, 67(3): 897-905. [Abstract] [Full-text]
35. Efficacy of complete decongestive therapy and manual lymphatic drainage on treatment-related lymphedema in breast cancer.
    Int J Radiat Oncol Biol Phys, 67(3): 841-6. [Abstract] [Full-text]
36. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.
    Genes Chromosomes Cancer, 46(4): 397-405. [Abstract] [Full-text]
37. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Pathol Int, 57(3): 126-32. [Abstract] [Full-text]
38. Dose-dependent protective effect of breast-feeding against breast cancer among ever-lactated women in Korea.
    Eur J Cancer Prev, 16(2): 124-9. [Abstract] [Full-text]
39. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan.
    Eur J Cancer Prev, 16(2): 116-23. [Abstract] [Full-text]
40. Residential magnetic fields, medication use, and the risk of breast cancer.
    Epidemiology, 18(2): 266-9. [Abstract] [Full-text]
41. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.
    Oncogene, 26(7): 1003-12. [Abstract] [Full-text]
42. 3rd PacRim Breast and Prostate Cancer Meeting. 31 October-4 November 2006, Fraser Island, Queensland, Australia.
    Expert Opin Investig Drugs, 16(3): 397-401. [Abstract] [Full-text]
43. Case study of the morphologic variation of circulating tumor cells.
    Hum Pathol, 38(3): 514-9. [Abstract] [Full-text]
44. AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma.
    J Surg Res, 138(1): 71-8. [Abstract] [Full-text]
45. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    J Surg Res, 138(1): 37-44. [Abstract] [Full-text]
46. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
    Lancet, 369(9561): 559-70. [Abstract] [Full-text]
47. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    J Clin Oncol, 25(6): 662-8. [Abstract] [Full-text]
48. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    J Clin Oncol, 25(6): 656-61. [Abstract] [Full-text]
49. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    J Clin Oncol, 25(6): 634-41. [Abstract] [Full-text]
50. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    J Clin Oncol, 25(6): 625-33. [Abstract] [Full-text]
51. The nuclear receptor interacting factor-3 transcriptional coregulator mediates rapid apoptosis in breast cancer cells through direct and bystander-mediated events.
    Cancer Res, 67(4): 1775-82. [Abstract] [Full-text]
52. Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer cell quiescence within bone marrow stroma.
    Cancer Res, 67(4): 1653-9. [Abstract] [Full-text]
53. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer.
    Cancer Res, 67(4): 1618-25. [Abstract] [Full-text]
54. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Cancer Res, 67(4): 1580-8. [Abstract] [Full-text]
55. Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells.
    Cancer Res, 67(4): 1520-6. [Abstract] [Full-text]
56. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Cancer Res, 67(4): 1487-93. [Abstract] [Full-text]
57. Adaptation of energy metabolism in breast cancer brain metastases.
    Cancer Res, 67(4): 1472-86. [Abstract] [Full-text]
58. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
    Cancer Res, 67(4): 1842-52. [Abstract] [Full-text]
59. Ductal carcinoma in situ in BRCA mutation carriers.
    J Clin Oncol, 25(6): 642-7. [Abstract] [Full-text]
60. Plasma phytoestrogens and subsequent breast cancer risk.
    J Clin Oncol, 25(6): 648-55. [Abstract] [Full-text]
61. The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells.
    Mol Pharmacol, 71(3): 843-51. [Abstract] [Full-text]
62. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma.
    Gynecol Oncol, 104(3): 557-63. [Abstract] [Full-text]
63. Dietary flavonoid intake and breast cancer risk among women on Long Island.
    Am J Epidemiol, 165(5): 514-23. [Abstract] [Full-text]
64. Use of oral conjugated estrogen alone and risk of breast cancer.
    Am J Epidemiol, 165(5): 524-9. [Abstract] [Full-text]
65. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
    Bioorg Med Chem, 15(6): 2269-82. [Abstract] [Full-text]
66. Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT).
    Maturitas, 56(3): 312-21. [Abstract] [Full-text]
67. Performance assessment for radiologists interpreting screening mammography.
    Stat Med, 26(7): 1532-51. [Abstract] [Full-text]
68. Docetaxel/anthracycline combinations for breast cancer treatment.
    Expert Opin Pharmacother, 8(4): 485-95. [Abstract] [Full-text]
69. Aesthetic outcome of different techniques of reconstruction following nipple-areola-preserving envelope mastectomy with immediate reconstruction.
    Plast Reconstr Surg, 119(3): 796-803. [Abstract] [Full-text]
70. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    J Natl Cancer Inst, 99(4): 283-90. [Abstract] [Full-text]
71. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
    J Natl Cancer Inst, 99(4): 272-82. [Abstract] [Full-text]
72. Relationship between number of breast cancer operations performed and 5-year survival after treatment for early-stage breast cancer.
    Am J Public Health, 97(3): 539-44. [Abstract] [Full-text]
73. Adequacy of communicating results from screening mammograms to African American and White women.
    Am J Public Health, 97(3): 531-8. [Abstract] [Full-text]
74. Critical review of the management of early-stage breast cancer in elderly women.
    Intern Med J, 37(3): 181-9. [Abstract] [Full-text]
75. Determination of critical dosimetric parameters for breast radiation using forward-planned segmented fields for intensity modulation.
    Med Dosim, 32(1): 23-32. [Abstract] [Full-text]
76. Treatment techniques for 3D conformal radiation to breast and chest wall including the internal mammary chain.
    Med Dosim, 32(1): 7-12. [Abstract] [Full-text]
77. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Pathol Int, 57(4): 183-9. [Abstract] [Full-text]
78. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
    Oncogene, 26(9): 1338-45. [Abstract] [Full-text]
79. Chromosome alterations associated with positive and negative lymph node involvement in breast cancer.
    Cancer Genet Cytogenet, 173(2): 114-21. [Abstract] [Full-text]
80. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
    Eur J Pharmacol, 559(1): 21-31. [Abstract] [Full-text]
81. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
    Biochim Biophys Acta, 1770(4): 601-8. [Abstract] [Full-text]
82. Mammary angiosarcomas: imaging findings in 24 patients.
    Radiology, 242(3): 725-34. [Abstract] [Full-text]
83. Unusual breast cancers: useful clues to expanding the differential diagnosis.
    Radiology, 242(3): 683-94. [Abstract] [Full-text]
84. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
    Radiology, 242(3): 698-715. [Abstract] [Full-text]
85. Malignant and benign breast masses on 3D US volumetric images: effect of computer-aided diagnosis on radiologist accuracy.
    Radiology, 242(3): 716-24. [Abstract] [Full-text]
86. Alcohol consumption and breast cancer risk in the Women's Health Study.
    Am J Epidemiol, 165(6): 667-76. [Abstract] [Full-text]
87. Reported residential pesticide use and breast cancer risk on Long Island, New York.
    Am J Epidemiol, 165(6): 643-51. [Abstract] [Full-text]
88. Technology insight: MammoSite--a new device for delivering brachytherapy following breast-conserving therapy.
    Nat Clin Pract Oncol, 4(3): 190-6. [Abstract] [Full-text]
89. Drug insight: VEGF as a therapeutic target for breast cancer.
    Nat Clin Pract Oncol, 4(3): 181-9. [Abstract] [Full-text]
90. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol, 25(7): 820-8. [Abstract] [Full-text]
91. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
    J Clin Oncol, 25(7): 829-36. [Abstract] [Full-text]
92. Axillary staging during surgery for breast cancer.
    Br J Surg, 94(3): 304-9. [Abstract] [Full-text]
93. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mol Carcinog, 46(3): 165-75. [Abstract] [Full-text]
94. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells.
    Biochem Pharmacol, 73(7): 934-42. [Abstract] [Full-text]

© 2004-2010 Breast Cancer Research Today. All Rights Reserved.